Ravindran S, Ranganathan SRKJNAS, Kannan SK, et al
"Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial." Lancet , 398(10313), 1811-1824
& Stay tuned Were continuing to expand horizons A new chapter for Immunotec in Europe is in the works Immunotec Inc #Switzerland Congratulations
Potential Benefits: In scientific research, BPC-157 has demonstrated promising effects on tissue regeneration, including tendons, ligaments, muscles, and bone
Always consult with your healthcare provider for personalized advice and treatment plans